Prevalence of Vulvovaginal Candidiasis Among Women with Diabetes mellitus in Ibadan, Oyo State, Nigeria


  • O. E. Adebiyi
  • A. Oluwadun
  • O. J. Daniel
  • R. S. Oritogun
  • A. A. Fasanmade


Candidiasis, Diabetes Mellitus, Prevalence, Vulvovaginitis, Women


Background: Diabetes mellitus predisposes to both bacterial and fungal infections, includingCandida species. Hitherto, Candida albicans has been identified as the most common opportunistic pathogen amongpatients with diabetes mellitus. More recently, Non-Candida albicans Candida (NCAC) species are increasingly recognized as the cause of candida infections.

Objective: To determine the prevalence of vulvovaginal candidiasis (VVC) as well as the species of Candida frequently identified among women with diabetes mellitus in Ibadan, Nigeria.

Methods: A cross-sectional study of 213 women diagnosed with diabetes mellitus was carried out in 2010. Direct microscopy and fungal cultures of high vaginal swabs were done using Sabouraud--Dextrose Agar and ChromAgar.

Results: The prevalence of VVC among 213 women with diabetic mellitus was 18.8% (40/213). The predominant Candida species isolated were Candida glabrata (30.0%), C. albicans and C. tropicalis (17.5%) each and C. Gulliermondii (15.0%). Diabetic women had higher rates of moderate and heavy growth of Candida density. Twenty-nine (72.5%) patients with candidiasis were symptomatic and the most common symptom was vulval/vaginal itching 48.3% (14/29).

Conclusion: This study put the prevalence rate of VVC among women with diabetes mellitus in Ibadan at 18.8%. The most common Candida species isolated was C.glabrata and majority of the patients were symptomatic.

Author Biographies

O. E. Adebiyi

Department of Medical Microbiology, University College Hospital, Ibadan, Oyo State

A. Oluwadun

Department of Medical Microbiology, Olabisi Onabanjo University, Sagamu, Ogun State

O. J. Daniel

Department of Community Medicine and Primary Care, Olabisi Onabanjo University Teaching Hospital Sagamu, Ogun State

R. S. Oritogun

Department of Community Medicine and Primary Care, Olabisi Onabanjo University Teaching Hospital Sagamu, Ogun State

A. A. Fasanmade

Department of Medicine, University College Hospital Ibadan, Oyo StatePrevalence of Vulvovaginal Candidiasis among women with Diabetes mellitus in Ibadan, Oyo State, Nigeria


Sacks DB. Carbohydrate. In: Burtis CA and Ashwood ER (editors). Tietz Textbook of Clinical Chemistry. 5th Edition, Philaldephia: WB Saunders Company. 2003: 427-461.

Cheesbrough M. Measurement of blood or plasma glucose. In: District Laboratory Practice in Tropical Countries. 2nd Edition, New York: Cambridge University Press. 2003 Part 1: 341- 348.

de Leon EM, Jacober SJ, Sobel JD, Foxman B. Prevalence and risk factors for vaginal Candida colonization in women with Type 1 and Type 2 diabetes. BMC Infect Dis 2002; 2:1.

Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 2003; 49: 53-70.

Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, et al. Prevalence of Candida glabrataand its response to Boric Acid vaginal suppositories in comparison with oral Fluconazole in patients with Diabetes and Vulvovaginal Candidiasis. Diabetes Care 2007; 30: 312-317.

White TC, Marr KA, Bowden RA. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.

Ruhnke M. Epidemiology of Candida albicans infections and role of non-Candida- albicans yeasts. Curr Drug Targets 2006; 7: 495–504.

Alteras I, Saryt E. Prevalence of pathogenic fungi in toe webs and nails of diabetic patients. Mycopathologia 1997; 67: 157-160.

Sonck CE, Somersalo O. The yeast flora of the anogenital region in diabetic girls. Arch Dermatol1963; 83: 214–220.

Nagesha CN, Ananthakrishna NC. Clinical and laboratory study of monilial vaginitis. Am J Obstet Gynecol 1970; 107: 1267–1268.

Peer AK, Hoosen AA, Seedat MA, Van-den-Ende J, Omar MA. Vaginal yeast infections in diabetic women. South Afr Med J 1993; 83: 727–729.

Jombo GT, Akpera MT, Hemba SH, Eyong KI. Symptomatic vulvovaginitis: knowledge, perceptions and treatment modalities among pregnant women of an urban settlement in West Africa. Afr J Clin Exp Microbiol 2011; 12: 32-37.

Nwadioha SI, Egah DZ, Alao OO, Iheanacho E. Risk factors for vaginal candidiasis among women attending primary health care centres of Jos, Nigeria. J Clin Med Res 2010; 2(7): 110-113.

Oyewole OA, Okoliegbe IN, Alkalil S, Isah P. Prevalence of vaginal candidiasis among pregnant women attending Federal University of Technology Minna, Nigeria. Bosso Clinic Research Journal of Pharmaceutical, Biological and Chemical Sciences 2013; 4(1): 113-120.

Oni AA, OgboluDO, Daini OA, Abdulrahaman N, Ugbe BA. Pattern of microbial colonization of the vagina of diabetics in Ibadan, Nigeria. Afr J Clin Exp Microbiol 2012; 13(2): 170-177.

Akah PA, Nnamani CE, Nnamani PO. Prevalence and treatment outcome of vulvovaginal candidiasis in pregnancy in a rural community in Enugu State. J Med Med Sci 2010; 1(10): 447-452.

Goswami R, Dadhwal V, Tejaswi S, Datta K, Paul A, Haricharan RN, et al. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J Infect 2000; 41: 162–166.

World Health Organization. Immunodeficiency, report of a scientific group. Technical Report Series 630. Geneva, 1978.

Goswamia D, Goswamib R, Banerjeec U, Dadhwala V, Miglanib S, Abdul Lattifc A, et al. Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal Candidiasis and their response to single dose oral fluconazole therapy. J Inf 2006; 52: 111–117.

Abi-said D, Anaissie E, Uzun O, Raad I, Pinzcowskin VS. The epidemiology of hematogenous candidiasis caused by different Candida species Clin Infect Dis 1997; 24: 1122-1128.

Schoofs AG, Odds FC, Colebunders R, Leven M and Goossens H. Cross-sectional study of oral Candida carriage in a human immunodeficiency virus seropositive population: predisposing factors, epidemiology and anti-fungal susceptibility. Mycoses 1998; 41: 203-211.

Ray D, Goswani R, Banerjee U, Dadwal V, Goswami D, Mandal P, et al. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care 2007; 30(2): 312-317.

Redondo-Lopez V, Lynch M, Schmitt C, Cook R, Sobel JD. Torulopsisglabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol 1990; 76: 651–655.

vanDen Bossche H, Marichal P, Odds FC, Le Jeune L, Coene MC. Characterization of an azole-resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992; 36: 2602–2610.

Fidel PL Jr, Vazquez JA, Sobel JD. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev 1999; 12: 80–96.

Vermitsky JP, Edlind TD. Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor. Antimicrob Agents Chemother 2004; 48: 3773–3781.